Margaret Horn - Oct 11, 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Signature
/s/ Jack Anders, as Attorney-in-fact for Margaret Horn
Stock symbol
RVMD
Transactions as of
Oct 11, 2024
Transactions value $
-$2,312,555
Form type
4
Date filed
10/15/2024, 05:31 PM
Previous filing
Sep 18, 2024
Next filing
Dec 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $183K +44.6K +33.73% $4.09 177K Oct 11, 2024 Direct F1, F2
transaction RVMD Common Stock Options Exercise $22K +5.37K +3.03% $4.09 182K Oct 11, 2024 Direct F1, F2
transaction RVMD Common Stock Sale -$2.52M -50K -27.42% $50.34 132K Oct 11, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -44.6K -100% $0.00 0 Oct 11, 2024 Common Stock 44.6K $4.09 Direct F1
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -5.37K -5.23% $0.00 97.4K Oct 11, 2024 Common Stock 5.37K $4.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024.
F2 Includes 77,300 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $50.00 to $50.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.